Company Overview and News

4
Emerald Health Therapeutics Announces Amendment to Pure Sunfarms’ Cultivation License, Substantially Expanding Cannabis Production Area to 225,000 Square Feet

2018-06-27 globenewswire
VANCOUVER, British Columbia, June 27, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSX-V:EMH) (OTCQX:EMHTF) (“Emerald”) and Village Farms International, Inc. (“Village Farms” or the “Company”) (TSX:VFF) (OTC:VFFIF) today announced that their 50/50 joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada an amendment to its cultivation license for its Delta 3 greenhouse in Delta, BC.
EMH TBQBF EMHTF VFFIF VFF

7
4 Marijuana-Related Companies That Just Raised Capital

2018-05-31 seekingalpha
We wanted to walk marijuana investors through the four companies, why they raised money, and more.
EMH TBQBF EMHTF VFFIF

5
Emerald Health Therapeutics Announces $16.8 Million Prospectus Sale; Concurrent Secondary Sale

2018-05-15 globenewswire
VICTORIA, British Columbia, May 15, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) ("Emerald" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 units of the Company (the “Units”) at a price of $4.20 per Unit for total gross proceeds of $16,800,000 (the “Offering”).
EMH TBQBF EMHTF VFFIF

0
BRIEF-Village Farms Says Pure Sunfarms Entered Into Cannabis Supply Agreement With Emerald Health Therapeutics

2018-04-30 reuters
* VILLAGE FARMS INTERNATIONAL INC - ANNOUNCED COMPANY’S 50/50 JOINT VENTURE WITH EMERALD HEALTH THERAPEUTICS, INC
VFFIF

4
Emerald Health Therapeutics Expands Strategic Investment in VANC

2018-04-17 globenewswire
VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) announced today that it has entered into a supply and distribution agreement (“Distribution Agreement”) with an affiliate of Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (“Emerald”), pursuant to which VANC was granted rights to sell and distribute certain proprietary endocannabinoid-supporting products in Canada to licensed pharmacies.
EMH TBQBF EMHTF NUVPF VFFIF NPH

4
TheBaron VII: Tough Market Movement Spells Opportunity

2018-03-28 seekingalpha
The overall portfolio had a weak month due mainly to one company's continued share price weakness, with slight moves downwards in most of the portfolio.
EMH MGRUF DR TBQBF EMHTF NWHUF CSEAF VFFIF DR.DB.A MFCSF

0
BRIEF-Village Farms International Reschedules Q4 And Year End Financial Results Conf Call

2018-03-19 reuters
* VILLAGE FARMS INTERNATIONAL - RESCHEDULES Q4 AND YEAR END FINANCIAL RESULTS CONF CALL TO APRIL 2, 2018 AT 11:00 A.M. ET
VFFIF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...